abstract：:Most antidepressants in clinical use are believed to function by enhancing neurotransmission of serotonin [5-hydroxytryptamine (5-HT)] and/or norepinephrine (NE) via inhibition of neurotransmitter reuptake. Agents that affect reuptake of both 5-HT and NE (serotonin-norepinephrine reuptake inhibitors) have been postula...

journal_title：International clinical psychopharmacology

authors： Trivedi MH,Desaiah D,Ossanna MJ,Pritchett YL,Brannan SK,Detke MJ

更新日期：2008-05-01 00:00:00

abstract：:Major depressive disorder (MDD) is currently the second most common cause of disability worldwide. Current treatment of MDD with selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors is limited by efficacy and tolerability issues, highlighting the unmet need in the treatment of patien...

journal_title：International clinical psychopharmacology

authors： Montgomery SA

更新日期：2008-03-01 00:00:00

abstract：:A review of published evidence of superior efficacy of a particular antidepressant in major depressive disorder may assist clinicians in making considered treatment choices. To identify such candidates, an international group of experts met to assess published evidence (identified through searches in Medline and Embas...

journal_title：International clinical psychopharmacology

authors： Montgomery SA,Baldwin DS,Blier P,Fineberg NA,Kasper S,Lader M,Lam RW,Lépine JP,Möller HJ,Nutt DJ,Rouillon F,Schatzberg AF,Thase ME

更新日期：2007-11-01 00:00:00

abstract：:Sparse data exist regarding the risks and benefits of treating bipolar-II depression with antidepressants alone. On the basis of studies of bipolar-I patients, treatment guidelines suggest antidepressants should be augmented with mood stabilizers. Whether these recommendations apply to bipolar-II is unclear. A post-ho...

journal_title：International clinical psychopharmacology

authors： Agosti V,Stewart JW

更新日期：2007-09-01 00:00:00

abstract：:Clinical trials are becoming increasingly international in scope. Global studies pose unique challenges in training and calibrating raters owing to language and cultural differences. Recent findings that poorly conducted interviews reduce study power, makes attention to raters' clinical skills critical. In this study,...

journal_title：International clinical psychopharmacology

authors： Jeglic E,Kobak KA,Engelhardt N,Williams JB,Lipsitz JD,Salvucci D,Bryson H,Bellew K

更新日期：2007-07-01 00:00:00

abstract：:Stevens-Johnson syndrome is a severe and potentially life-threatening cutaneous reaction associated with lamotrigine. The incidence of developing Stevens-Johnson syndrome during lamotrigine therapy is low. On the basis of the glutamate and dopamine neuron dysregulation hypothesis in schizophrenia, we propose new strat...

journal_title：International clinical psychopharmacology

authors： Shen YC,Chen SJ,Lin CC,Chen CH

更新日期：2007-07-01 00:00:00

abstract：:The use of certain atypical antipsychotics has been associated with metabolic disturbances. We have assessed the evolution of body weight and glycaemia during a 6-month randomized comparative trial of amisulpride and olanzapine. Three hundred and seventy-seven adult patients with schizophrenia were randomized to eithe...

journal_title：International clinical psychopharmacology

authors： Peuskens J,De Hert M,Mortimer A,SOLIANOL Study Group.

更新日期：2007-05-01 00:00:00

abstract：:The objective of this study was to evaluate the effectiveness and tolerability of aripiprazole use in child and adolescent psychiatric inpatients. This was a naturalistic, retrospective evaluation of the discharged patients treated with aripiprazole on the child and adolescent unit at the Austin State Hospital. To be ...

journal_title：International clinical psychopharmacology

authors： Gibson AP,Crismon ML,Mican LM,Fischer C

更新日期：2007-03-01 00:00:00

abstract：:This analysis characterizes patients with schizophrenia or schizoaffective disorder treated with risperidone who met remission criteria. In a 50-week, open-label trial, stable patients received long-acting injectable risperidone every 2 weeks. Remission criteria included severity (absent-mild ratings on core symptoms ...

journal_title：International clinical psychopharmacology

authors： Docherty JP,Bossie CA,Lachaux B,Bouhours P,Zhu Y,Lasser R,Gharabawi GM

更新日期：2007-01-01 00:00:00

abstract：:Small studies have shown positive effects from adding a variety of antipsychotic agents in patients with obsessive-compulsive disorder who are unresponsive to treatment with serotonin reuptake inhibitors. The evidence, however, is contradictory. This paper reports a meta-analysis of existing double-blind randomized pl...

journal_title：International clinical psychopharmacology

authors： Fineberg NA,Stein DJ,Premkumar P,Carey P,Sivakumaran T,Vythilingum B,Seedat S,Westenberg H,Denys D

更新日期：2006-11-01 00:00:00

abstract：:Duloxetine, an inhibitor of serotonin and norepinephrine reuptake, has been approved for the treatment of major depressive disorder. In this analysis, data from eight, double-blind, placebo-controlled duloxetine trials were pooled, and the response to duloxetine treatment (40-120 mg/day) was compared between patients ...

journal_title：International clinical psychopharmacology

authors： Perahia DG,Kajdasz DK,Royer MG,Walker DJ,Raskin J

更新日期：2006-09-01 00:00:00

abstract：:Sleep disorders, such as insomnia and nightmares, are common problems in post-traumatic stress disorder (PTSD), exert a strong negative influence on the quality of life and are a great challenge for clinical psychiatry. Several studies have reported on the efficacy of drugs for the treatment of PTSD-related sleep diso...

journal_title：International clinical psychopharmacology

authors： van Liempt S,Vermetten E,Geuze E,Westenberg HG

更新日期：2006-07-01 00:00:00

abstract：:Body dysmorphic disorder (BDD) is a relatively common and impairing disorder. Selective serotonin reuptake inhibitors (SRIs) appear selectively efficacious for BDD, but pharmacotherapy research is limited, and escitalopram has not been studied. Fifteen subjects with BDD were treated with escitalopram and assessed with...

journal_title：International clinical psychopharmacology

authors： Phillips KA

更新日期：2006-05-01 00:00:00

abstract：:Several cardiovascular risk factors have been linked to antipsychotic treatment and cardiovascular mortality is increased in these patients compared to the general population. The full metabolic syndrome (or its components) is associated with an increased risk of cardiovascular disorders. The prevalence of the metabol...

journal_title：International clinical psychopharmacology

authors： Hägg S,Lindblom Y,Mjörndal T,Adolfsson R

更新日期：2006-03-01 00:00:00

abstract：:We report the case of a patient with schizophrenia who developed urinary hesitancy and eventually urinary retention, 6 months after continuous treatment with ziprasidone; he had been administered no other medication during this time. The micturition difficulties resolved immediately upon discontinuation of ziprasidone...

journal_title：International clinical psychopharmacology

authors： Xomalis D,Bozikas VP,Garyfallos G,Nikolaidis N,Giouzepas J,Fokas K

更新日期：2006-01-01 00:00:00

abstract：:The introduction of second generation antipsychotics (SGA) represents a major advance in the treatment of schizophrenia. Concerns about the metabolic and cardiovascular adverse effects of the SGA have been widely disseminated. The benefits and risks of these drugs have been studied with a focus on particular organ sys...

journal_title：International clinical psychopharmacology

authors： Barak Y,Swartz M,Plopsky I

更新日期：2005-11-01 00:00:00

abstract：:Recent evidence has demonstrated the efficacy of pegylated interferon-alpha (IFN-alpha) in treating hepatitis C virus infection. Neuropsychiatric complications commonly occur during the course of IFN treatment, with depressive symptoms usually appearing within the first 12 weeks. Few cases of the pegylated interferon-...

journal_title：International clinical psychopharmacology

authors： Sockalingam S,Balderson K

更新日期：2005-09-01 00:00:00

abstract：:The present study aimed to compare health outcomes and tolerability according to antipsychotic medication (olanzapine, risperidone or an oral typical antipsychotic) after 6 months of treatment in a group of 919 schizophrenic patients who had never previously been treated with antipsychotics. Demographic and clinical p...

journal_title：International clinical psychopharmacology

authors： Gasquet I,Haro JM,Novick D,Edgell ET,Kennedy L,Lepine JP,SOHO Study Group.

更新日期：2005-07-01 00:00:00

abstract：:The selective serotonin reuptake inhibitors (SSRIs) have well-established antidepressant activity and have also demonstrated efficacy in a number of anxiety disorders, including panic disorder. The SSRIs, escitalopram and sertraline, are well-tolerated and movement disorders are rarely associated with their use. We pr...

journal_title：International clinical psychopharmacology

authors： Altindag A,Yanik M,Asoglu M

更新日期：2005-05-01 00:00:00

abstract：:The present study aimed to systematically compare overall loss to follow-up, discontinuation rates because of adverse events and discontinuation rates because of a lack of efficacy in published studies assessing the efficacy and tolerability of selective serotonin reuptake inhibitors (SSRIs) compared to other second-g...

journal_title：International clinical psychopharmacology

authors： Gartlehner G,Hansen RA,Carey TS,Lohr KN,Gaynes BN,Randolph LC

更新日期：2005-03-01 00:00:00

abstract：:We report a case of myoclonus induced by quetiapine. A 64-year-old man with schizophrenia developed myoclonic jerks when given higher doses of quetiapine. These movements were dose-related and completely abated on reducing the dose. To our knowledge, these movements have not been reported previously as an adverse effe...

journal_title：International clinical psychopharmacology

authors： Velayudhan L,Kirchner V

更新日期：2005-03-01 00:00:00

abstract：:The pattern of brain metabolic changes produced by olanzapine has yet to be described, despite the theoretical and clinical interest of this new antipsychotic. We studied a group of 17 schizophrenic patients who underwent two fluoro-deoxyglucose-positron emission tomography (FDG-PET) studies under two different condit...

journal_title：International clinical psychopharmacology

authors： Molina V,Gispert JD,Reig S,Pascau J,Martínez R,Sanz J,Palomo T,Desco M

更新日期：2005-01-01 00:00:00

abstract：:We compared the antidepressant efficacy and patient tolerance of two different doses of milnacipran (75 mg and 150 mg daily) in 66 outpatients with major depression, using the 17-item Hamilton Depression Rating Scale (HDRS). Only new patients who had never experienced frank depressive episodes before, or those who had...

journal_title：International clinical psychopharmacology

authors： Kanemoto K,Matsubara M,Yamashita K,Tarao Y,Inada E,Sekine T

更新日期：2004-11-01 00:00:00

abstract：:The effects of an abrupt interruption of agomelatine, a new melatonergic/serotonergic antidepressant, were explored in a double-blind, placebo-controlled study. Paroxetine was used as active control. After 12 weeks of double-blind treatment with agomelatine 25 mg/day or paroxetine 20 mg/day, sustained remitted depress...

journal_title：International clinical psychopharmacology

authors： Montgomery SA,Kennedy SH,Burrows GD,Lejoyeux M,Hindmarch I

更新日期：2004-09-01 00:00:00

abstract：:Recent meta-analytic work suggests atypical antipsychotics may be clinically superior to conventional antipsychotics, although many stable patients remain on conventional antipsychotic treatment. A long-acting atypical agent may benefit patients in realms of both advanced medication delivery and mechanism of action. I...

journal_title：International clinical psychopharmacology

authors： van Os J,Bossie CA,Lasser RA

更新日期：2004-07-01 00:00:00

abstract：:Forty-one delirious patients who received risperidone treatment and 36 who received haloperidol treatment were retrospectively analysed. Ten-point visual analog scales (scored 0 for none to 10 for extremely severe) for hyperactive and hypoactive syndromes of delirium were used for efficacy evaluation. Psychiatrists sc...

journal_title：International clinical psychopharmacology

authors： Liu CY,Juang YY,Liang HY,Lin NC,Yeh EK

更新日期：2004-05-01 00:00:00

abstract：:Medication adherence with antipsychotics is adversely impacted by the burden of untoward adverse effects. In particular, sexual side-effects may interfere with compliance, but are often underreported by patients. Sexual dysfunction related to hyperprolactinemia is commonly described, but ejaculatory disturbance due to...

journal_title：International clinical psychopharmacology

authors： Loh C,Leckband SG,Meyer JM,Turner E

更新日期：2004-03-01 00:00:00

abstract：:We report that perospirone may have had positive effects on the obesity of three patients with schizophrenia and on the fasting blood sugar (FBS) and HbA1C of two of them who had type 2 diabetes mellitus. ...

journal_title：International clinical psychopharmacology

authors： Nishida M,Nakamura M

更新日期：2004-01-01 00:00:00

abstract：:The treatment of negative symptoms of schizophrenia presents a major clinical challenge. This review examines the evidence pertaining to the efficacy, tolerability and safety of adding selective serotonin reuptake inhibitors (SSRIs) to antipsychotic agents in the treatment of negative symptoms in schizophrenia. Import...

journal_title：International clinical psychopharmacology

authors： Silver H

更新日期：2003-11-01 00:00:00

abstract：:While most depressed patients are prescribed a selective serotonin reuptake inhibitor (SSRI) as an initial treatment, the use of SSRIs as a second or third-line treatment for depression is not as prevalent. This trial assessed the efficacy of sertraline for patients with treatment-resistant depression (TRD) or patient...

journal_title：International clinical psychopharmacology

authors： Papakostas GI,Petersen T,Worthington JJ,Roffi PA,Alpert JE,Fava M,Nierenberg AA

更新日期：2003-09-01 00:00:00

abstract：:Although life prevalence of substance use disorders among patients with schizophrenia is close to 50%, few studies have been carried out to date to identify an integrated pharmacological treatment for this comorbidity. So far, the most promising results, that we report here, have been obtained with clozapine. To a les...

journal_title：International clinical psychopharmacology

authors： Potvin S,Stip E,Roy JY

更新日期：2003-05-01 00:00:00

abstract：:Treatment-resistant depression is an important clinical problem presenting a major challenge to clinical psychiatry. While several strategies have been attempted, including medication switch, antidepressant polypharmacy and various augmentative regimens, success remains limited. Amantadine (AMN), an agent traditionall...

journal_title：International clinical psychopharmacology

authors： Stryjer R,Strous RD,Shaked G,Bar F,Feldman B,Kotler M,Polak L,Rosenzcwaig S,Weizman A

更新日期：2003-03-01 00:00:00

abstract：:To compare the efficacy and tolerability of moclobemide versus paroxetine for the treatment of depression with comorbid anxiety disorders. Outpatients fulfilling DSM-III-R criteria for major depression or dysthymia and for a co-occurring comorbid anxiety disorder (panic disorder, generalized anxiety disorder or obsess...

journal_title：International clinical psychopharmacology

authors： Pini S,Amador XF,Dell'Osso L,Baldini Rossi N,Cassano P,Savino M,Cassano GB

更新日期：2003-01-01 00:00:00

abstract：:Recent studies have shown that the use of subscales derived from the Hamilton Depression (HAM-D) rating scale are just as reliable and enhance sensitivity for detecting response and remission after antidepressant treatment. The purpose of the present study was to determine if the responses on two items of the HAM-D sc...

journal_title：International clinical psychopharmacology

authors： Silverstone PH,Entsuah R,Hackett D

更新日期：2002-11-01 00:00:00

abstract：:Social dysfunction is often associated with depressive disorders and its evaluation is an important measure of treatment outcome. The aim of this study was to assess the effect of two treatments, venlafaxine and amitriptyline, on the social functioning of depressed patients. Twenty-eight outpatients, meeting criteria ...

journal_title：International clinical psychopharmacology

authors： Gorenstein C,Andrade L,Moreno RA,Artes R

更新日期：2002-07-01 00:00:00

abstract：:The utility of milnacipran in the treatment of major depression has been the subject of an extensive clinical development programme. Comparative studies with tricyclic antidepressant drugs have demonstrated equivalent efficacy, with improved tolerability, in particular with respect to autonomic effects. In comparison ...

journal_title：International clinical psychopharmacology

authors： Bisserbe JC

更新日期：2002-06-01 00:00:00

abstract：:Serotonin reuptake inhibitors (SSRI), such as venalafaxine and paroxetine, are used in the treatment of generalized anxiety disorder (GAD). Patients with GAD frequently have comorbid psychiatric disorders, such as depression. SSRIs are effective in the treatment of a variety of anxiety disorders and depression. Citalo...

journal_title：International clinical psychopharmacology

authors： Varia I,Rauscher F

更新日期：2002-05-01 00:00:00

abstract：:Using spectral analysis of heart rate, several studies have shown that panic disorder patients are characterized by a reduced heart rate variability (HRV), indicative of abnormalities in autonomous nervous system (ANS) function. We recently reported that patients with panic disorder, who did not respond to pharmacothe...

journal_title：International clinical psychopharmacology

authors： Slaap BR,Boshuisen ML,van Roon AM,den Boer JA

更新日期：2002-03-01 00:00:00

abstract：:It has been suggested that the atypical antipsychotic drugs may induce a rapid improvement in individuals with melancholic depression. This might reflect a specific or non-specific effect on mood and other parameters. To examine this issue, ten consecutive patients, for whom olanzapine augmentation was judged a clinic...

journal_title：International clinical psychopharmacology

authors： Parker G

更新日期：2002-03-01 00:00:00

abstract：:The purpose of this study was to compare the efficacy and safety of risperidone and haloperidol in treatment-resistant chronic schizophrenic patients. Subjects (n = 78) who met DSM-III criteria for schizophrenia were randomly assigned to receive 6 mg/day of risperidone or 20 mg/day of haloperidol for 12 weeks. Clinica...

journal_title：International clinical psychopharmacology

authors： Zhang XY,Zhou DF,Cao LY,Zhang PY,Wu GY,Shen YC

更新日期：2001-11-01 00:00:00